Page 12 - أبحاث كلية الصيدلة 2016-2020

2016 Publications

Journal of Health Specialties
2016;4:52-5.

The hypotensive and uricosuric effect of valsartan compared to losartan in gout
patients

Anas Bahnassi, Amjad Abuirmeileh, Ayman Abuirmeileh
Objective: Our objective was to investigate the possible relationship between previous or
concurrent use of losartan or valsartan and gout in newly diagnosed patients.
Materials and Methods: Thirty-two newly-diagnosed gout patients, whose blood pressure
was controlled using losartan for at least 3 months were included. The study was divided into
3 stages; stage I where patients were controlled for 3 months using losartan (50 mg/day), stage
II - where patients were switched from losartan to valsartan (80 mg/day) with their blood
pressure controlled and maintained for another 3 months using valsartan instead of losartan
and stage III - where patients were switched back to losartan (50 mg/day). All changes in
clinical and biochemical parameters were reported.
Results: There were no significant changes in biochemical parameters such as liver enzymes,
serum levels of creatinine, sodium and bicarbonate. Serum levels of potassium and uric acid
were elevated. Valsartan significantly increased potassium and uric acid levels at the end of
stage II (P = 0.024). Since these adverse effects did not disappear after changing back to
losartan at the end of stage III, we performed an additional 3-month follow-up stage. The
subjects required a period of 6 months to return to levels seen at the end of stage I.
Conclusion: Losartan showed a slightly higher hypotensive effect than valsartan in patients
newly diagnosed with gout. It also resulted in lower uric acid levels.
https://www.thejhs.org/article.asp?issn=2468
6360;year=2016;volume=4;issue=1;spage=52;epage=55;aulast=Bahnassi;type=3

8